Δημοσίευση

Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.

ΤίτλοςSubretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.
Publication TypeJournal Article
Year of Publication2014
AuthorsSymeonidis, C., Dastiridou A., Konidaris V., Brazitikos P., & Androudi S.
JournalOcul Immunol Inflamm
Volume22
Issue6
Pagination497-500
Date Published2014 Dec
ISSN1744-5078
Λέξεις κλειδιάAntibodies, Monoclonal, Humanized, Dose-Response Relationship, Drug, Fluorescein Angiography, Fundus Oculi, Humans, Male, Middle Aged, Off-Label Use, Ranibizumab, Retina, Tomography, Optical Coherence, Uveitis, Posterior, Visual Acuity
Abstract

PURPOSE: The subretinal fibrosis and uveitis (SFU) syndrome is a rare multifocal posterior uveitis characterized by progressive subretinal fibrosis and significant visual loss.METHODS: Slit-lamp examination, dilated fundoscopy, fluorescein angiography, Spectral Domain-Optical Coherence Tomography (SD-OCT) and laboratory testing were employed.RESULTS: A 52-year-old male presented with bilateral (best-corrected visual acuity: 2/10) visual loss. Clinical examination revealed bilateral anterior uveitis with posterior synechiae and posterior uveitis. Medical workup revealed no pathologic findings. Treatment included 1 gr intravenous prednisone followed by oral prednisone, immunosuppresive therapy and three ranibizumab injections in the right eye with no improvement. One year later, there was significant subretinal fibrosis. In the second year follow-up, the picture was slightly worse, with persisting bilateral macular edema and fibrosis.CONCLUSIONS: This is the first SFU syndrome report monitored with SD-OCT. This novel imaging modality can localize the lesion level, guide the therapeutic approach and may prove helpful in assessing disease prognosis.

DOI10.3109/09273948.2013.841959
Alternate JournalOcul. Immunol. Inflamm.
PubMed ID24131103

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.